No Data
Propanc Biopharma To File CTA In Australia For Phase 1b Study In 30–40 Advanced Cancer Patients; Plans Two Phase 2 Studies In Pancreatic And Ovarian Cancers With 60 Patients Each
Propanc Biopharma, Inc. CEO Forecasts Medical Breakthroughs Against Pancreatic Cancer Over Next Decade
Express News | Propanc Biopharma Inc - Plans Two Phase 2 Studies in Pancreatic and Ovarian Cancers With 60 Patients Each
Express News | Propanc Biopharma Inc - to File Cta in Australia for Phase 1B Study in 30–40 Advanced Cancer Patients
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
Trending Industry Today: Strategy Leads Losses In Crypto Treasury Stocks
15447843 : chart looks right. i’ll regret not buying but i dont touch bio anymore. gl